# Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/temporary-scheduling-orders-controlled-substances/ > **Published:** 2026-06-22T14:56:47-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:38:32-04:00 > **Clinical Summary:** Explore temporary scheduling orders for controlled substances, including 2-fluorodeschloroketamine, and their impact on drug regulation and public health. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis policyDEA scheduling[controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/)Schedule I placementfederal drug regulationtemporary scheduling ordersynthetic drug legislation Clinical Summary The Drug Enforcement Administration has temporarily placed 2-fluorodeschloroketamine (2-FDCK), a synthetic ketamine analog, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, effective immediately. This action addresses the emergence of 2-FDCK as a novel psychoactive substance being marketed and distributed as a legal alternative to ketamine and other controlled drugs. While this scheduling decision targets a ketamine analog rather than cannabis directly, it reflects the regulatory framework through which the DEA manages novel synthetic drugs that may be developed to circumvent existing controlled substance laws, a mechanism potentially relevant to cannabinoid analogs and synthetic cannabinoids. Clinicians should be aware that illicit novel psychoactive substances marketed as “legal” alternatives may pose significant [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) risks and unknown toxicity profiles compared to regulated pharmaceutical options. The takeaway for clinicians is to remain vigilant about emerging synthetic drugs in their patient populations and to educate patients that unregulated substances marketed as legal alternatives carry unpredictable safety risks and lack the quality assurance of FDA-approved medications. Clinical Perspective 💊 The DEA’s temporary scheduling of 2-fluorodeschloroketamine (2-FDCK) into Schedule I reflects the ongoing challenge of regulating novel synthetic drugs designed to circumvent existing legislation, though clinicians should recognize that this action primarily affects illicit markets rather than approved medical practice. While the pharmacological similarity to ketamine raises theoretical safety concerns, the lack of clinical data on human effects, abuse patterns, and potential harms means we cannot yet draw direct parallels to established ketamine use in anesthesia or emerging psychiatric applications. Healthcare providers should remain aware that synthetic ketamine analogs represent a shifting landscape of [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/), potentially complicating toxicology interpretation and patient [risk assessment](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/), though standard urine drug screens are unlikely to detect 2-FDCK. The key clinical implication is that providers caring for patients with [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) should maintain heightened suspicion for novel synthetic drugs when standard screening is negative, consider 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+2-Fluorodeschloroketamine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+2-Fluorodeschloroketamine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Policy Watch: 20 Regulatory Updates — June 21, 2026](https://cedclinic.com/schedules-controlled-substances-placement-june-2026/) - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) Detailed analysis of the DEA’s temporary scheduling of 2-FDCK and its implications for controlled substance regulation. [Read More](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-designation/) Explore the DEA’s scheduling actions on synthetic cannabinoids like CUMYL-PEGACLONE and their regulatory context. [Explore Now](https://cedclinic.com/cumyl-pegaclone-schedule-i-designation/) [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) Comprehensive coverage of recent Schedule I placements of multiple synthetic cannabinoids by the DEA. [Learn More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).